Literature DB >> 24820732

New daily persistent headache: an update.

Todd D Rozen1.   

Abstract

New daily persistent headache is a primary headache disorder marked by a unique temporal profile which is daily from onset. For many sufferers this is their first ever headache. Very little is known about the pathogenesis of this condition. It might be a disorder of abnormal glial activation with persistent central nervous system inflammation and it may be a syndrome that occurs in individuals who have a history of cervical hypermobility. At present there is no known specific treatment and many patients go for years to decades without any improvement in their condition despite aggressive therapy. This article will present an up-to-date overview of new daily persistent headache on the topics of clinical presentation, treatment, diagnostic criteria, and presumed pathogenesis. It will also provide some of the authors own treatment suggestions based on recognized triggering events and some suggestions for future clinical trials.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24820732     DOI: 10.1007/s11916-014-0431-6

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  12 in total

Review 1.  New daily persistent headache.

Authors:  Peter J Goadsby; Christopher Boes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

2.  The International Classification of Headache Disorders: 2nd edition.

Authors: 
Journal:  Cephalalgia       Date:  2004       Impact factor: 6.292

3.  The International Classification of Headache Disorders, 3rd edition (beta version).

Authors: 
Journal:  Cephalalgia       Date:  2013-07       Impact factor: 6.292

4.  The clinical characteristics of new daily persistent headache.

Authors:  D Li; T D Rozen
Journal:  Cephalalgia       Date:  2002-02       Impact factor: 6.292

Review 5.  Calcitonin gene-related peptide (CGRP) and migraine.

Authors:  Paul L Durham
Journal:  Headache       Date:  2006-06       Impact factor: 5.887

6.  Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan.

Authors:  Y Takase; M Nakano; C Tatsumi; T Matsuyama
Journal:  Cephalalgia       Date:  2004-11       Impact factor: 6.292

Review 7.  Convergence of cervical and trigeminal sensory afferents.

Authors:  Elcio J Piovesan; Pedro A Kowacs; Michael L Oshinsky
Journal:  Curr Pain Headache Rep       Date:  2003-10

8.  Mexiletine for refractory chronic daily headache: a report of nine cases.

Authors:  Michael J Marmura; Frank C Passero; William B Young
Journal:  Headache       Date:  2008-09-12       Impact factor: 5.887

9.  Refining clinical features and therapeutic options of new daily persistent headache: a retrospective study of 63 patients in India.

Authors:  Sanjay Prakash; Samir Saini; Kaushikkumar Ramanlal Rana; Pinaki Mahato
Journal:  J Headache Pain       Date:  2012-05-27       Impact factor: 7.277

10.  Post-infectious new daily persistent headache may respond to intravenous methylprednisolone.

Authors:  Sanjay Prakash; Nilima D Shah
Journal:  J Headache Pain       Date:  2010-02       Impact factor: 7.277

View more
  4 in total

Review 1.  New Daily Persistent Headache: a Diagnostic and Therapeutic Odyssey.

Authors:  Emily J Riddle; Jonathan H Smith
Journal:  Curr Neurol Neurosci Rep       Date:  2019-03-19       Impact factor: 5.081

2.  Differences in Pediatric Headache Prescription Patterns by Diagnosis.

Authors:  Jonathan Rabner; Allison Ludwick; Alyssa LeBel
Journal:  Paediatr Drugs       Date:  2018-06       Impact factor: 3.022

3.  Is new daily persistent headache a fallout of somatization? An observational study.

Authors:  Ravi Uniyal; Rohit Chhirolya; Adarsh Tripathi; Prabhakar Mishra; Vimal Kumar Paliwal
Journal:  Neurol Sci       Date:  2021-05-15       Impact factor: 3.307

Review 4.  Update on New Daily Persistent Headache.

Authors:  Hida Nierenburg; Lawrence C Newman
Journal:  Curr Treat Options Neurol       Date:  2016-06       Impact factor: 3.972

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.